Wells Fargo Maintains Equal-Weight on NovoCure, Lowers Price Target to $15
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Larry Biegelsen maintains NovoCure (NASDAQ:NVCR) with a Equal-Weight and lowers the price target from $20 to $15.
Wells Fargo analyst Larry Biegelsen maintains NovoCure (NASDAQ:NVCR) with a Equal-Weight and lowers the price target from $20 to $15.